Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differential antigen presentation in tumor immunity.

S Schatten, J A Drebin, R D Granstein

    Federation Proceedings
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel.

    The British journal of dermatology·2019
    Same author

    FoxP3 in T<sub>reg</sub> cell biology: a molecular and structural perspective.

    Clinical and experimental immunology·2019
    Same author

    Lymph node evaluation and survival after curative-intent resection of duodenal adenocarcinoma: A matched cohort study.

    European journal of cancer (Oxford, England : 1990)·2016
    Same author

    Calcitonin gene-related peptide: key regulator of cutaneous immunity.

    Acta physiologica (Oxford, England)·2014
    Same author

    Genetic and molecular aspects of demyelination.

    Immunology today·2014
    Same author

    The I-J subregion and surveillance.

    Immunology today·2014

    Tumor S1509a triggers immune responses in some mice but suppressor T cells (Ts) in others. Findings suggest antigen presentation by specific antigen-presenting cells (APCs) dictates immune outcomes, influencing tumor immunity.

    Area of Science:

    • Immunology
    • Cancer Research
    • T cell immunology

    Background:

    • The S1509a tumor elicits distinct immune responses in different mouse strains.
    • Immune A/J mice develop cell-mediated immunity, while nonimmune mice generate suppressor T cells (Ts).
    • Previous research indicates I-A+ antigen-presenting cells (APCs) present S1509a tumor antigen, activating immune T cells.

    Purpose of the Study:

    • To investigate the role of antigen-presenting cells (APCs) in determining immune responses to S1509a tumor.
    • To explore the mechanism by which suppressor T cells (Ts) inhibit tumor immunity.
    • To examine the potential involvement of I-J+ APCs in Ts activation.

    Main Methods:

    • Administration of anti-I-A antibodies in conjunction with tumor challenge.

    Related Experiment Videos

  • Analysis of T cell activation and suppressor T cell generation.
  • Evaluation of immunologic effects of cyclophosphamide and UV radiation.

    • Main Results:

    • Anti-I-A antibodies prevented T cell activation by I-A+ APCs presenting S1509a tumor antigen.
    • Administration of anti-I-A antibodies induced suppressor T cells (Ts) following tumor challenge.
    • Evidence supports the hypothesis that tumor antigen presented on I-J+ APCs activates Ts, inhibiting tumor immunity.

    Conclusions:

    • The type of antigen-presenting cell (APC) involved in antigen presentation is critical in determining the immune response to S1509a tumor.
    • Suppressor T cells (Ts), potentially activated by I-J+ APCs, play a significant role in suppressing anti-tumor immunity.
    • Further investigation into APC subsets and their role in immune regulation is warranted.